Last $2.42 USD
Change Today -0.06 / -2.42%
Volume 14.9K
BIOC On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

biocept inc (BIOC) Snapshot

Open
$2.39
Previous Close
$2.48
Day High
$2.51
Day Low
$2.38
52 Week High
02/5/14 - $10.02
52 Week Low
10/1/14 - $2.27
Market Cap
10.8M
Average Volume 10 Days
21.6K
EPS TTM
--
Shares Outstanding
4.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCEPT INC (BIOC)

Related News

No related news articles were found.

biocept inc (BIOC) Related Businessweek News

No Related Businessweek News Found

biocept inc (BIOC) Details

Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company is also developing other OncoCEE CTC tests, including OncoCEE-LU for lung cancer; OncoCEE-GA for gastric cancer; OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma. Biocept, Inc. sells its products through its direct sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States, as well as biopharma companies. It has collaboration agreement with Rosetta Genomics, Ltd. to evaluate microRNAs from circulating tumor cells. The company was founded in 1997 and is headquartered in San Diego, California.

27 Employees
Last Reported Date: 03/28/14
Founded in 1997

biocept inc (BIOC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $66.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $227.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $208.2K
Compensation as of Fiscal Year 2013.

biocept inc (BIOC) Key Developments

Biocept, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Biocept, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $10,274 against $31,922 a year ago. Loss from operating was $3,711,629 against $2,374,476 a year ago. Loss before income taxes was $3,859,794 against $2,860,191 a year ago. Net loss was $3,859,794 or $0.87 per basic and diluted share against $2,860,191 or $15.72 per basic and diluted share a year ago. Revenues decrease was primarily related to lower Dana Farber Cancer Institute sample volume as the trial's enrollment approaches completion. The increase in net loss was primarily due to the deployment of the Company's sales and marketing function, as well as increased research and development costs driven by efforts to bring new test panels and biomarkers to market. For the nine months, the company reported revenue of $57,794 against $115,445 a year ago. Loss from operating was $10,142,666 against $5,885,885 a year ago. Loss before income taxes was $11,983,705 against $6,760,374 a year ago. Net loss was $11,984,505 or $3.12 per basic and diluted share against $6,761,174 or $37.11 per basic and diluted share a year ago.

Biocept, Inc. Launches Lung Cancer Liquid Biopsy Testing

Biocept, Inc. announced the launch of its lung cancer liquid biopsy testing that will be performed at the Company's CLIA-certified and CAP-accredited laboratory. By launching blood-based biomarker testing for non-small cell lung cancer (NSCLC), along with the previously commercialized breast cancer offering, Biocept is providing options for health care providers and researchers when a tumor biopsy is not available, is unsafe to perform or when additional information is desired. For patients with recurrent or newly diagnosed metastatic lung cancer, accurate identification of genomic biomarker information is a key piece of information that clinicians need when making treatment decisions. A challenge for physicians has been availability of tissue from the surgical biopsy that is required to perform the biomarker testing. This limitation occurs as a result of tumor location or health of the patient. When lung biopsies are attempted, there is a 19.3% risk of complication such as a collapsed lung or an infection. Managing these complications quadruples the cost of care. In comparison, the cost of a simple blood draw is nominal, and poses little risk for patients, and the Company believes it has the potential to simultaneously save cost and improve outcomes for the health care system. The Company's first CLIA-validated assay for lung cancer will be testing for ALK fusions on CTCs captured in Biocept's patented device. ALK is incorporated into the testing guidelines utilized by oncologists when making treatment decisions in NSCLC patients. ALK positive patients now have targeted treatment options with two key drugs that have been approved by the FDA: the first is Pfizer's Xalkori (Crizotinib) and the second is Novartis's Zykadia (ceritinib), and others are in development. The company currently plans to offer additional biomarkers for lung cancer that physicians use when making treatment decisions before the end of the year and during 2015, including EGFR mutations, Ros1 fusions, KRAS mutations, and EGFR and MET amplification. EGFR mutation status, like ALK, is a biomarker included in guidelines that oncologists follow to determine the best treatment plan for a patient. Patients who have EGFR mutations are eligible for Tyrosine Kinase Inhibitors such as Tarceva(R) from Genentech or Iressa(R) from AstraZeneca. In addition, the Company is validating important resistance markers for these targeted therapies that they expect to be used most often when physicians are monitoring patients.

Biocept, Inc. to Report Q3, 2014 Results on Nov 13, 2014

Biocept, Inc. announced that they will report Q3, 2014 results After-Market on Nov 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $2.42 USD -0.06

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $1.88 USD +0.45
BioMerieux €85.95 EUR -0.18
Daiichi Sankyo Co Ltd ¥1,697 JPY -5.50
Fluidigm Corp $33.14 USD +0.83
Illumina Inc $188.20 USD +1.98
View Industry Companies
 

Industry Analysis

BIOC

Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 140.6x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit www.biocept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.